HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[AMBIZYGO: phase II study of high dose liposomal amphotericin B (AmBisome) [10 mg/kg/j] efficacy against zygomycosis].

AuthorsF Lanternier, O Lortholary
JournalMedecine et maladies infectieuses (Med Mal Infect) Vol. 38 Suppl 2 Pg. S90-1 (Jun 2008) ISSN: 0399-077X [Print] France
Vernacular TitleAMBIZYGO: étude de phase II de l'efficacité d'une posologie initiale élevée d'amphotéricine B liposomale (AmBisome) [10 mg/kg/j] dans le traitement des zygomycoses.
PMID18598882 (Publication Type: Clinical Trial, Phase II, Journal Article)
Chemical References
  • liposomal amphotericin B
  • Amphotericin B
Topics
  • Amphotericin B (therapeutic use, toxicity)
  • Female
  • Humans
  • Male
  • Patient Selection
  • Treatment Outcome
  • Zygomycosis (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: